Unpacking Ozempic: The Debate on Health, Hype, and Disability

Ozempic was developed with the intent to treat type 2 diabetes, but today, it’s become one of the biggest weight-loss crazes in North America. Nisreen Abdel-Majid digs into what happens when a medication meant to save lives becomes a massive cultural trend, who it affects, and how severely. We hear from Mousa Abdul Samar, Pharmacist and Manager at Deen Pharmacy, who offers a vital perspective on Ozempic’s intended use and the risks of misuse. Bill Shakleton, a retired AMI colleague living with type 2 diabetes, shares his personal journey with the drug and how the weight-loss buzz affects him directly. And Amy Amantea, an artist and accessibility advocate who's had type 1 diabetes her whole life, reflects on what it means to navigate treatment and public perception around Ozempic. Nisreen asks her guests for perspectives on who gets Ozempic, who needs it, and what we aught to pay more attention to around quick health fixes. About AMIAMI is a media company that entertains, informs and empowers Canadians with disabilities through three broadcast services — AMI-tv and AMI-audio in English and AMI-télé in French — and streaming platform AMI+. Our vision is to establish AMI as a leader in the offering of accessible content, providing a voice for Canadians with disabilities through authentic storytelling, representation and positive portrayal. To learn more visit AMI.ca and AMItele.ca.Find more great AMI Original Content on AMI+Connect with Accessible Media Inc. online:X /Twitter @AccessibleMediaInstagram @AccessibleMediaInc / @AMI-audioFacebook at @AccessibleMediaIncTikTok @AccessibleMediaIncEmail [email protected] Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.